US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Militia Long/Short Equity ETF

35.81

-0.4800-1.32%

Post-market: 35.810.00000.00%19:57 EDT

Volume:400.39K

Turnover:14.39M

Market Cap:428.29M

PE:- -

High:36.29

Open:36.16

Low:35.72

Close:36.29

52wk High:39.39

52wk Low:25.85

Shares:11.96M

Float Shares:11.96M

Volume Ratio:2.13

T/O Rate:3.35%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Relay Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Outlines Anticipated 2026 Milestones

New England Journal of Medicine Publishes First-in-Human Rezatapopt Data Showing Selective Reactivation of Mutant p53 in Advanced Solid Tumors

Antengene Announces Clinical Collaboration with Junshi Biosciences to Explore the Synergistic Potential of ATG-037 (Oral CD73 Inhibitor) In Combination with JS207 (PD-1/VEGF BsAb)

Iovance Biotherapeutics Explodes Over 20% — Early Trial Data Sparks Investor Frenzy

Crescent Biopharma Announces First Patient Dosed in ASCEND Phase 1/2 Clinical Trial of CR-001 for the Treatment of Advanced Solid Tumors

NovaBridge Doses First Patient in Global, Randomized Phase 2 Study of Givastomig Combined with Immunochemotherapy in Patients with 1L Metastatic Gastric Cancer

Genmab Publishes 2025 Annual Report

Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results

Press Release: ORYZON Announces Appointment of Rolando Gutierrez-Esteinou, M.D., as Chief Medical Officer for CNS

Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update

Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC

Cogent Biosciences to Initiate New Drug Application (NDA) Submission for Bezuclastinib Under Real-Time Oncology Review (RTOR)

Antengene Presents at JPM: Strong Clinical Data Update and Strategic Focus on Next-Generation ADCs and TCEs

C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways

ACCENT DATA PRESENTED AT 2026 ASCO GASTROINTESTINAL CANCER SYMPOSIUM

Press Release: Rigel Provides Business Update and 2026 Outlook

Press Release: Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026

Cellectis Announces 2026 Strategy and Catalysts

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ORR/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ORR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","market":"US","secType":"STK","nameCN":"Militia Long/Short Equity ETF","latestPrice":35.81,"timestamp":1774641600000,"preClose":36.29,"halted":0,"volume":400387,"hourTrading":{"tag":"盘后","latestPrice":35.81,"preClose":35.81,"latestTime":"19:57 EDT","volume":313,"amount":11206.313,"timestamp":1774655850909,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.01322678423808203,"floatShares":11960000,"shares":11960000,"eps":0,"marketStatus":"Market Closed","change":-0.48,"latestTime":"03-27 16:00:00 EDT","open":36.16,"high":36.29,"low":35.72,"amount":14394852.358289002,"amplitude":0.015707,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774857600000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":36.29,"sharesOutstanding":12900000,"nav":36.65,"aum":435402000,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":36.18,"preClose":36.29,"latestTime":"09:19 EDT","volume":11,"amount":397.98,"timestamp":1774617580197,"change":-0.11,"changeRate":-0.003031,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":35.81,"preClose":35.81,"latestTime":"19:57 EDT","volume":313,"amount":11206.313,"timestamp":1774655850909,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":2.12915,"impliedVol":0.0274,"impliedVolPercentile":0.0357},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","floatShares":11960000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":2.12915,"shares":11960000,"dividePrice":0,"high":36.29,"amplitude":0.015707,"preClose":36.29,"low":35.72,"week52Low":25.85,"pbRate":"--","week52High":39.39,"institutionHeld":0,"latestPrice":35.81,"eps":0,"divideRate":0,"volume":400387,"delay":0,"ttmEps":0,"open":36.16,"prevYearClose":34.16,"prevWeekClose":35.79,"prevMonthClose":39.08,"prevQuarterClose":34.16,"fiveDayClose":35.79,"twentyDayClose":39.08,"sixtyDayClose":34.345},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ORR\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ORR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ORR\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ORR\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2614611859","title":"ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2614611859","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614611859?lang=en_us&edition=fundamental","pubTime":"2026-02-27 21:00","pubTimestamp":1772197200,"startTime":"0","endTime":"0","summary":"- Clinical development for both the investigational CD47-inhibitor evorpacept and the novel EGFR-targeted antibody-drug conjugate ALX2004 remains on track following strong 2025 execution; company anti","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/27/3246481/0/en/ALX-Oncology-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BMG7P819.SGD","IE00BMG7P702.HKD","IE00BMG7P694.USD","BK4195","BK4080","BK4097","LU0456854461.SGD","ASH","OS","LU0266512127.USD","BK4144","BK4161","CRC","IE00BD4GTW91.USD","LU2463526074.USD","IE00BMG7P926.USD","BK4231","BK4211","IE00BMG7P587.USD","CR","BK4566","IE00BD4GTV84.USD","ADC","TRP","BK4203","IE00BD4GTT62.SGD","ORR","SITC","HR","BK4225","BK4109","PFS","BK4213","ALX"],"gpt_icon":0},{"id":"2614071916","title":"Relay Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Outlines Anticipated 2026 Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2614071916","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614071916?lang=en_us&edition=fundamental","pubTime":"2026-02-27 05:05","pubTimestamp":1772139900,"startTime":"0","endTime":"0","summary":"Initial Phase 1 data of zovegalisib in PIK3CA-driven vascular anomalies expected to be announced in first half of 2026 Breast cancer triplet data and frontline Phase 3 plans expected to be announced i","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/26/3246092/0/en/Relay-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Outlines-Anticipated-2026-Milestones.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BHPRN162.USD","BK4139","BK4195","BK4135","PFS","WT","BK4563","BK4211","ORR","RLAY"],"gpt_icon":0},{"id":"2614044421","title":"New England Journal of Medicine Publishes First-in-Human Rezatapopt Data Showing Selective Reactivation of Mutant p53 in Advanced Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2614044421","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614044421?lang=en_us&edition=fundamental","pubTime":"2026-02-26 21:00","pubTimestamp":1772110800,"startTime":"0","endTime":"0","summary":"PRINCETON, N.J., Feb.  26, 2026  (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of s","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/26/3245511/0/en/New-England-Journal-of-Medicine-Publishes-First-in-Human-Rezatapopt-Data-Showing-Selective-Reactivation-of-Mutant-p53-in-Advanced-Solid-Tumors.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0757428866.USD","IE00B66KJ199.SGD","IE00B7SZL793.SGD","AEIS","BK4157","IE00B19Z4B17.USD","IE0031619046.USD","ORR","LU1815336091.USD"],"gpt_icon":0},{"id":"2614722974","title":"Antengene Announces Clinical Collaboration with Junshi Biosciences to Explore the Synergistic Potential of ATG-037 (Oral CD73 Inhibitor) In Combination with JS207 (PD-1/VEGF BsAb)","url":"https://stock-news.laohu8.com/highlight/detail?id=2614722974","media":"prnewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614722974?lang=en_us&edition=fundamental","pubTime":"2026-02-25 08:30","pubTimestamp":1771979400,"startTime":"0","endTime":"0","summary":"SHANGHAI and HONG KONG, Feb. 25, 2026 /PRNewswire/ -- Antengene Corporation Limited  , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune diseases, solid tumors and hematological malignancies, announced that it has entered into a clinical collaboration agreement with Shanghai Junshi Biosciences Co., Ltd . Under the collaboration, the parties will jointly evaluate the synergistic therapeutic potential of Antengene's ATG-037, an oral small-molecule CD73 inhibitor, in combination with Junshi Biosciences' JS207, a recombinant humanized anti-PD-1/VEGF bispecific antibody, in patients with solid tumors in Mainland China, with the goal of identifying clinical signals across multiple tumor types.","market":"hk","thumbnail":"https://mma.prnewswire.com/media/2355066/ANTENGENE_EN_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2355066/ANTENGENE_EN_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/antengene-announces-clinical-collaboration-with-junshi-biosciences-to-explore-the-synergistic-potential-of-atg-037-oral-cd73-inhibitor-in-combination-with-js207-pd-1vegf-bsab-302695694.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B66KJ199.SGD","LU0963586101.USD","IND.AU","CRS","IND","HCC","RCC","BK4097","IE00B7SZL793.SGD","BK7095","BK4023","BK4187","LU2065731478.USD","OS","CRS.AU","IE0031619046.USD","IE00B19Z4B17.USD","LU1169589451.USD","BK4006","LU1169590202.USD","ORR","PD","ORR.AU"],"gpt_icon":0},{"id":"2614742143","title":"Iovance Biotherapeutics Explodes Over 20% — Early Trial Data Sparks Investor Frenzy","url":"https://stock-news.laohu8.com/highlight/detail?id=2614742143","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614742143?lang=en_us&edition=fundamental","pubTime":"2026-02-25 03:14","pubTimestamp":1771960440,"startTime":"0","endTime":"0","summary":"Iovance shares jump 29% after early cancer trial shows 50% response rate. The company plans FDA talks and a new study in 2026.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/02/24/Medical-Team-Analyzing-Mri-Or-Ct-Scans-O.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/02/24/Medical-Team-Analyzing-Mri-Or-Ct-Scans-O.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/health-care/26/02/50828663/iovance-biotherapeutics-explodes-over-20-early-trial-data-sparks-investor-frenzy","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/26/02/50828663/iovance-biotherapeutics-explodes-over-20-early-trial-data-sparks-investor-frenzy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["LU0320765489.SGD","IE00BJJMRY28.SGD","LU0320765646.SGD","BK4217","LU1894683348.USD","BK4131","LU0149725797.USD","IE00BJJMRX11.SGD","BK4139","BK4585","LU0061475181.USD","IE00B19Z3581.USD","LU0211331839.USD","SMA","BK4532","IE00B7KXQ091.USD","IE00B7SZLL34.SGD","BK4588","IE00BFSS8Q28.SGD","LU1585245621.USD","UPS","LU1074936037.SGD","LU1430594728.SGD","BK4550","LU0070302665.USD","ORR","LU2237438978.USD","BK4534","LU2133065610.SGD","IE0002270589.USD","BK4559","IE0004445015.USD","IOVA","LU1162221912.USD","IE00B19Z3B42.SGD","LU0208291251.USD","IE00BFSS7M15.SGD","LU1894683264.USD"],"gpt_icon":0},{"id":"2612446154","title":"Crescent Biopharma Announces First Patient Dosed in ASCEND Phase 1/2 Clinical Trial of CR-001 for the Treatment of Advanced Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2612446154","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612446154?lang=en_us&edition=fundamental","pubTime":"2026-02-18 20:30","pubTimestamp":1771417800,"startTime":"0","endTime":"0","summary":"ASCEND to evaluate CR-001, a PD-1 x VEGF bispecific antibody, in multiple solid tumor types, including NSCLC and gastrointestinal and gynecological cancers in first-line and previously treated patient","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/18/3240098/0/en/Crescent-Biopharma-Announces-First-Patient-Dosed-in-ASCEND-Phase-1-2-Clinical-Trial-of-CR-001-for-the-Treatment-of-Advanced-Solid-Tumors.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B7SZL793.SGD","BK4195","LU1815336091.USD","PFS","ORR","BK4211","IE00B19Z4B17.USD","OS","IE00B66KJ199.SGD","BK4157","IE0031619046.USD","BK4097","LU0757428866.USD","AEIS"],"gpt_icon":0},{"id":"2612460136","title":"NovaBridge Doses First Patient in Global, Randomized Phase 2 Study of Givastomig Combined with Immunochemotherapy in Patients with 1L Metastatic Gastric Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2612460136","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612460136?lang=en_us&edition=fundamental","pubTime":"2026-02-18 05:05","pubTimestamp":1771362300,"startTime":"0","endTime":"0","summary":"Global, randomized Phase 2 study to evaluate the addition of givastomig, a CLDN18.2 x 4-1BB bispecific antibody (8 mg/kg and 12 mg/kg) to standard of care immunochemotherapy in patients with first lin","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/17/3239738/0/en/NovaBridge-Doses-First-Patient-in-Global-Randomized-Phase-2-Study-of-Givastomig-Combined-with-Immunochemotherapy-in-Patients-with-1L-Metastatic-Gastric-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4097","BK4195","OS","IHC","PFS","BK4211","ORR","BK4162"],"gpt_icon":0},{"id":"2612465023","title":"Genmab Publishes 2025 Annual Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2612465023","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612465023?lang=en_us&edition=fundamental","pubTime":"2026-02-18 00:01","pubTimestamp":1771344060,"startTime":"0","endTime":"0","summary":"Company Announcement COPENHAGEN, Denmark; February 17, 2026 – Genmab A/S (Nasdaq: GMAB) announced today the publication of its Annual Report for 2025. Below is a summary of business progress in 2025, ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/17/3239535/0/en/Genmab-Publishes-2025-Annual-Report.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PFS","BK4195","BK4211","PROC","ORR","BK4007"],"gpt_icon":0},{"id":"2612745754","title":"Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2612745754","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612745754?lang=en_us&edition=fundamental","pubTime":"2026-02-17 21:00","pubTimestamp":1771333200,"startTime":"0","endTime":"0","summary":"SUMMIT NDA for bezuclastinib in patients with NonAdvSM submitted in December 2025; APEX NDA submission for bezuclastinib in patients with AdvSM on track for 1H 2026PEAK NDA initiated for bezuclastinib","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/17/3239198/0/en/Cogent-Biosciences-Reports-Recent-Business-Highlights-and-Fourth-Quarter-and-Full-Year-2025-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CCOI","LU0124384867.USD","LU1861219969.SGD","LU1978683503.SGD","LU1720051108.HKD","BK4532","LU2463526074.USD","BK4109","LU0724618433.USD","LU2360107325.USD","BK4588","LU1720051017.SGD","ASH","ORR","ON","IE00BFMHRM44.USD","LU1670627923.USD","BK4089","BK4605","LU1861220033.SGD","LU2357305700.SGD","LU1861215975.USD","BK4512","LU0348723411.USD","IE00BZ199S13.USD","LU1861214812.USD","BK4585","LU1548497426.USD","LU1854103824.USD","LU1670628061.USD","LU1854104046.USD","IND","BK4141","IE00BD6J9T35.USD","LU2298322129.HKD"],"gpt_icon":0},{"id":"2610929187","title":"Press Release: ORYZON Announces Appointment of Rolando Gutierrez-Esteinou, M.D., as Chief Medical Officer for CNS","url":"https://stock-news.laohu8.com/highlight/detail?id=2610929187","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610929187?lang=en_us&edition=fundamental","pubTime":"2026-02-12 21:00","pubTimestamp":1770901200,"startTime":"0","endTime":"0","summary":"-- Based in New Jersey , to lead ORYZON's CNS clinical development. MADRID and CAMBRIDGE, Mass., Feb. 12, 2026  -- Oryzon Genomics, S.A. , a clinical-stage biopharmaceutical company and global leader in epigenetics, today announced the appointment of Rolando Gutierrez-Esteinou, M.D., as Chief Medical Officer, CNS Programs. Dr. Gutierrez-Esteinou is a Harvard-trained psychiatrist and an accomplished global clinical development executive with more than 20 years of leadership experience advancing neuroscience and psychiatry-focused drug development programs. He brings deep expertise in late-stage clinical execution, regulatory strategy, and pathways to market approval.\"It is a privilege to join Oryzon as Chief Medical Officer and help advance vafidemstat, the onl","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4081","BK4022","R","BK4135","EMA","ORR","USA","BK4232","BK4090","CNS","BK4156","CMT"],"gpt_icon":0},{"id":"2608871324","title":"Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2608871324","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608871324?lang=en_us&edition=fundamental","pubTime":"2026-02-03 21:00","pubTimestamp":1770123600,"startTime":"0","endTime":"0","summary":"April 10, 2026 Target Action Date for RP1 in Advanced MelanomaWOBURN, Mass., Feb.  03, 2026  (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/03/3230977/0/en/Replimune-Reports-Fiscal-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORR"],"gpt_icon":0},{"id":"2607740100","title":"Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2607740100","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607740100?lang=en_us&edition=fundamental","pubTime":"2026-01-29 05:01","pubTimestamp":1769634060,"startTime":"0","endTime":"0","summary":"First patients dosed in DAYBreak registrational program for bexobrutideg in relapsed/refractory CLL Presented Phase 1 results at ASH 2025 that support bexobrutideg’s potential best-in-class profile in","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/28/3228040/0/en/Nurix-Therapeutics-Reports-Fourth-Quarter-and-Fiscal-Year-2025-Financial-Results-and-Provides-a-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2023250504.SGD","LU0158827781.USD","LU0289739343.SGD","WM","LU0158827948.USD","LU1917777945.USD","LU0124676726.USD","BK4585","LU2308191902.HKD","LU2362540622.SGD","LU2089283258.USD","LU0347712357.USD","LU2229751404.USD","LU0511384066.AUD","LU1989772923.USD","BK4139","LU2106854487.HKD","BK4566","LU1585245621.USD","LU2092937221.SGD","LU0472753341.HKD","LU0289961442.SGD","LU2028103732.USD","LU2298064838.USD","NRIX","LU2362541513.USD","BK4534","LU2240825500.USD","LU2362541273.HKD","LU1939255532.USD","LU2041044095.USD","LU1923621640.USD","BK4195","LU1430594728.SGD","LU0689626769.HKD","LU1623119135.USD","LU2089284900.SGD","BK4211","ORR","PFS","BK4120","ASH","BK4533","LU2463526074.USD","LU2023250843.SGD","LU2413666426.HKD","LU1721428933.USD","LU0057025933.USD","LU1712237335.SGD","LU0069063385.USD"],"gpt_icon":0},{"id":"2606919789","title":"Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC","url":"https://stock-news.laohu8.com/highlight/detail?id=2606919789","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606919789?lang=en_us&edition=fundamental","pubTime":"2026-01-27 20:05","pubTimestamp":1769515500,"startTime":"0","endTime":"0","summary":"-Onvansertib added to FOLFIRI/bev first-line standard of care regimen showed dose-dependent improvement in overall response rates and durability trends as measured by progression-free survival in pati","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/27/3226345/0/en/Cardiff-Oncology-Announces-Positive-Update-from-its-Randomized-Phase-2-Trial-of-Onvansertib-in-First-line-RAS-mutated-mCRC.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1978683503.SGD","IE00BZ199S13.USD","BK4588","LU1861215975.USD","IE00BD6J9T35.USD","LU1720051017.SGD","BK4141","IE00BFMHRM44.USD","BK4195","LU2298322129.HKD","PFS","BK4211","LU1854103824.USD","LU1548497426.USD","LU1854104046.USD","LU2360107325.USD","LU0124384867.USD","LU2357305700.SGD","BK4512","LU0724618433.USD","ON","BK4161","LU1861220033.SGD","BK4585","BK4605","ORR","LU0054578231.USD","LU1861219969.SGD","LU0053671581.USD","LU1861214812.USD","ITT","LU0348723411.USD","LU1720051108.HKD"],"gpt_icon":0},{"id":"2604113780","title":"Cogent Biosciences to Initiate New Drug Application (NDA) Submission for Bezuclastinib Under Real-Time Oncology Review (RTOR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2604113780","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604113780?lang=en_us&edition=fundamental","pubTime":"2026-01-20 21:00","pubTimestamp":1768914000,"startTime":"0","endTime":"0","summary":"- PEAK trial first ever study to demonstrate statistical significance over an active comparator in GIST patients, with bezuclastinib plus sunitinib combination demonstrating mPFS of 16.5 months and OR","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/20/3221679/0/en/Cogent-Biosciences-to-Initiate-New-Drug-Application-NDA-Submission-for-Bezuclastinib-Under-Real-Time-Oncology-Review-RTOR.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CCOI","BK4195","LU1670627923.USD","LU1670628061.USD","PFS","BK4211","BK4089","ORR","BK4532"],"gpt_icon":0},{"id":"2603400937","title":"Antengene Presents at JPM: Strong Clinical Data Update and Strategic Focus on Next-Generation ADCs and TCEs","url":"https://stock-news.laohu8.com/highlight/detail?id=2603400937","media":"prnewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603400937?lang=en_us&edition=fundamental","pubTime":"2026-01-16 09:00","pubTimestamp":1768525200,"startTime":"0","endTime":"0","summary":"SHANGHAI and HONG KONG, Jan. 16, 2026 /PRNewswire/ -- Antengene Corporation Limited , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines forautoimmune disease, solid tumors and hematological malignancies indications, announced that it recently presented at the 44th Annual J.P. Morgan Healthcare Conference held in San Francisco. At the conference, Antengene shared the latest data and clinical development plans for its core clinical asset, ATG-022 , as well as R&D progress on ATG-125 , its steric hindrance masking AnTenGager T cell engager  platform, and other key preclinical programs.Advancing clinical development across 1L to 3L gastric cancer: Antengene is currently conducting the Phase I/II CLINCH study and","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/antengene-presents-at-jpm-strong-clinical-data-update-and-strategic-focus-on-next-generation-adcs-and-tces-302662555.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0211328371.USD","IE00BHPRN162.USD","LU0345770993.USD","LU1629891620.HKD","LU2023250843.SGD","LU2746668461.USD","ACR.AU","IE0034235188.USD","LU2756315664.SGD","IND.AU","LU0106261372.USD","IE00B3S45H60.SGD","LU0251132253.USD","LU0683600562.USD","LU1084165304.USD","IE00BN8TJ469.HKD","LU1670627923.USD","ORR.AU","LU0208291251.USD","LU0345769631.USD","LU2264538146.SGD","CR","LU2106854487.HKD","LU0170899867.USD","LU0820561818.USD","LU0868494617.USD","IE00BFXG1179.USD","CRS.AU","IE00BKVL7J92.USD","LU2065731478.USD","LU1974910355.USD","ORR","LU0820562030.AUD","LU1244550494.USD","BK4534","ACR","BK7508","LU1064131342.USD","IE0034235295.USD","LU0345770308.USD","LU0417517546.SGD","LU0943347566.SGD","LU0106831901.USD","IND","CRS","LU0006306889.USD","LU2430703095.HKD","BK4581","LU0787776722.HKD"],"gpt_icon":0},{"id":"2603613538","title":"C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways","url":"https://stock-news.laohu8.com/highlight/detail?id=2603613538","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603613538?lang=en_us&edition=fundamental","pubTime":"2026-01-14 20:00","pubTimestamp":1768392000,"startTime":"0","endTime":"0","summary":"Cemsidomide Phase 2 MOMENTUM Trial On Track to Initiate in Q1 2026; Recommended Phase 2 Dose is 100 g Cemsidomide Phase 1b Trial in Combination With Elranatamab On Track to Initiate in Q2 2026 Interna","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/14/3218491/0/en/C4-Therapeutics-Outlines-Strategic-Milestones-to-Advance-Cemsidomide-as-a-Potential-Best-in-Class-IKZF1-3-Degrader-and-Discovery-Strategy-Focused-on-Novel-Targets-in-Clinically-Val.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORR","CCCC","BK4139"],"gpt_icon":0},{"id":"2602054358","title":"ACCENT DATA PRESENTED AT 2026 ASCO GASTROINTESTINAL CANCER SYMPOSIUM","url":"https://stock-news.laohu8.com/highlight/detail?id=2602054358","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602054358?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:45","pubTimestamp":1768225500,"startTime":"0","endTime":"0","summary":"HIGHLIGHTS Results from the Phase 2a ACCENT trial in pancreatic cancer have been presented at the specialist conference ASCO Gastrointestinal Cancer SymposiumUpdated data analysis continues to show th","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/12/3216936/0/en/ACCENT-DATA-PRESENTED-AT-2026-ASCO-GASTROINTESTINAL-CANCER-SYMPOSIUM.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PFS","INNMF","BK4139","BK4211","BK4195","ORR"],"gpt_icon":0},{"id":"2602851062","title":"Press Release: Rigel Provides Business Update and 2026 Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2602851062","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602851062?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:05","pubTimestamp":1768223100,"startTime":"0","endTime":"0","summary":"-- Preliminary fourth quarter 2025 total revenue of approximately $69.8. million, including net product sales of $65.4 million and contract. RBC-TI was achieved by 33%  of evaluable transfusion dependent. $275 to $290 million, including net product sales of $255 to $265 million,\"2025 was an excellent year for Rigel, marked by strong commercial execution with record net product sales; significant financial progress, including continued profitability and generation of $77 million in cash; and meaningful clinical advancement of R289 in lower-risk MDS, where we shared encouraging Phase 1b data,\" said Raul Rodriguez, Rigel's president and CEO. \"In 2026, we plan to continue to execute across all areas of the business -- driving sustained commercial performance, supporting our expanding clinical programs with a solid financial foundation, delivering preliminary results from the dose expansion phase of our R289 study and continuing to explore opportunities to add new products to our portfolio.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","BK4232","LU2463526074.USD","ASH","BK4109","HTB","OS","R","BK4139","BK4211","RIGL","BK4097","ORR"],"gpt_icon":0},{"id":"2602515003","title":"Press Release: Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2602515003","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602515003?lang=en_us&edition=fundamental","pubTime":"2026-01-12 18:37","pubTimestamp":1768214220,"startTime":"0","endTime":"0","summary":"-- Cabozantinib franchise achieves approximately $2.123 billion in preliminary U.S. net product revenues for fiscal year 2025 --. -- Fiscal year 2026 net product revenues guidance of $2.325 billion - $2.425 billion --. -- Presentation and webcast at J.P. Morgan 2026 Healthcare Conference tomorrow, Monday, January 12 at 5:15 p.m. PT / 8:15 p.m. ET --. Exelixis, Inc.  today announced its preliminary unaudited financial results for the fiscal year 2025, provided financial guidance for fiscal year 2026 and delivered an update on its business. Exelixis anticipates 2026 will be a significant year of clinical, regulatory and commercial progress as the company grows its current cabozantinib business, works toward building a potential second commercial franchise with zanzalintinib and moves its earlier stage pipeline forward. As outlined at its December 2025 R&D Day, the company seeks to leverage its diverse pipeline and key clinical collaborations to build next-generation oncology franchises t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","BK4588","R","BK4232","LU2065171311.SGD","BK4195","RCC","EXEL","BK4211","BK4213","BK4613","ORR","BK4116","CRC","BK4097","BK4585","OS","PFS","BK4560","LU2065171402.SGD","BK4022","BK4139","LU2065169927.USD","BK4548","LU0266512127.USD","BK4607","BK4554","LU2065170008.USD","LU2286300806.USD","LU0456854461.SGD","NET"],"gpt_icon":0},{"id":"2602139483","title":"Cellectis Announces 2026 Strategy and Catalysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2602139483","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602139483?lang=en_us&edition=fundamental","pubTime":"2026-01-09 05:30","pubTimestamp":1767907800,"startTime":"0","endTime":"0","summary":"NEW YORK, Jan.  08, 2026  (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to de","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/08/3215815/0/en/Cellectis-Announces-2026-Strategy-and-Catalysts.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4109","ORR","OS","TIL","BK4505","LU2463526074.USD","BK4097","ASH","BK4139","CLLS"],"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":2,"totalSize":140,"code":"91000000","status":"200"}]}}